written on 31.03.2014
Tags:
,

Supreme Court to hear Teva's Copaxone appeal

TAGS: ,

The Supreme Court has agreed to hear an appeal of a lower court's decision to invalidate Teva's Copaxone patent, which if restored will shield the drug until September 2015. The decision may, in the least, leave competitors wary of proceeding with generics, giving Teva more time to convert patients to a new, long-acting version of the treatment.

Latest Report